Measuring anxiety: are we getting what we need?

Balon, Richard

doi:10.1002/da.20077

Cited by 20 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Study protocols, strategies of measurement and cutoff levels for both subclinical atherosclerosis and mental symptoms assessments vary widely in literature [5,7,51,52]. There is substantial heterogeneity among studies.…”

Section: Discussionmentioning

confidence: 99%

Anxiety and depressive symptoms are associated with higher carotid intima-media thickness. Cross-sectional analysis from ELSA-Brasil baseline data

et al. 2015

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Anxiety and depressive symptoms are associated with higher carotid intima-media thickness. Cross-sectional analysis from ELSA-Brasil baseline data

et al. 2015

View full text Add to dashboard Cite

“…That is, nearly all of the measures to assess anxiety symptoms are of a dimensional nature. However, many scales lack a theoretical basis, have unsatisfactory psychometric properties (Balon, ), lack homogeneity in format and content, and are quite lengthy (LeBeau et al, ). For that reason, the Anxiety Disorder Subgroup of the DSM‐5 Anxiety, Obsessive‐Compulsive Spectrum, Post‐traumatic, and Dissociative Disorders Work Group developed a set of dimensional measures for the anxiety disorders, the so called DSM‐5 Dimensional Anxiety Scales.…”

Section: Introductionmentioning

confidence: 99%

The DSM‐5 Dimensional Anxiety Scales in a Dutch non‐clinical sample: psychometric properties including the adult separation anxiety disorder scale

Möller

Bögels

2016

Int J Methods Psych Res

View full text Add to dashboard Cite

With DSM‐5, the American Psychiatric Association encourages complementing categorical diagnoses with dimensional severity ratings. We therefore examined the psychometric properties of the DSM‐5 Dimensional Anxiety Scales, a set of brief dimensional scales that are consistent in content and structure and assess DSM‐5‐based core features of anxiety disorders. Participants (285 males, 255 females) completed the DSM‐5 Dimensional Anxiety Scales for social anxiety disorder, generalized anxiety disorder, specific phobia, agoraphobia, and panic disorder that were included in previous studies on the scales, and also for separation anxiety disorder, which is included in the DSM‐5 chapter on anxiety disorders. Moreover, they completed the Screen for Child Anxiety Related Emotional Disorders Adult version (SCARED‐A). The DSM‐5 Dimensional Anxiety Scales demonstrated high internal consistency, and the scales correlated significantly and substantially with corresponding SCARED‐A subscales, supporting convergent validity. Separation anxiety appeared present among adults, supporting the DSM‐5 recognition of separation anxiety as an anxiety disorder across the life span. To conclude, the DSM‐5 Dimensional Anxiety Scales are a valuable tool to screen for specific adult anxiety disorders, including separation anxiety. Research in more diverse and clinical samples with anxiety disorders is needed. © 2016 The Authors International Journal of Methods in Psychiatric Research Published by John Wiley & Sons Ltd.

show abstract

“…This 20-item questionnaire is a benchmark assessment for state anxiety. 17,18 The testing procedure was repeated 7 days later, with each participant receiving the alternative treatment. Participants were encouraged to maintain the same training regimen for the 7 days before each trial.…”

Section: Methodsmentioning

confidence: 99%

Effect of Pseudoephedrine on 800-m-Run Times of Female Collegiate Track Athletes

Berry¹,

Wagner²

2012

International Journal of Sports Physiology and Performance

View full text Add to dashboard Cite

Context:Pseudoephedrine (PSE) is an over-the-counter decongestant that might have ergogenic effects. The World Anti-Doping Agency has prohibited large doses (>150 μg/mL) of PSE, while the National College Athletic Association (NCAA) does not include it on their banned-substance list.Purpose:This study examined the effect of body-weight dosing of PSE on 800-m-run times of NCAA female runners.Methods:Fifteen NCAA female track athletes volunteered to participate in the randomized, double-blind, crossover design. Participants were given 2.5 mg/kg PSE or placebo in trials separated by a week. Ninety minutes postingestion, participants completed an 800-m individual time trial on an indoor track. Finishing time was recorded with an automated video timing device. Heart rate and anxiety state scores were recorded immediately after each trial.Results:Fourteen runners completed both trials, and 1 was an outlier: N = 13. Despite the dose being well above normal therapeutic levels (144 ± 17 mg), there was no significant difference (P = .92) in 800-m times between PSE (2:39.447 ± 9.584) and placebo (2:39.372 ± 9.636) trials, in postexercise heart rate (P = .635; PSE = 177.9 ± 14.5 beats/min, placebo = 178.4 ± 18.5 beats/min), or in anxiety-state levels (P = .650; PSE = 38.4 ± 11.6, placebo = 38.1 ± 8.8).Conclusion:A 2.5-mg/kg dose of PSE had no effect on 800-m performance for female NCAA runners. More research is needed to determine if PSE should be a specified banned substance.

show abstract

Measuring anxiety: are we getting what we need?

Cited by 20 publications

References 35 publications

Anxiety and depressive symptoms are associated with higher carotid intima-media thickness. Cross-sectional analysis from ELSA-Brasil baseline data

Anxiety and depressive symptoms are associated with higher carotid intima-media thickness. Cross-sectional analysis from ELSA-Brasil baseline data

The DSM‐5 Dimensional Anxiety Scales in a Dutch non‐clinical sample: psychometric properties including the adult separation anxiety disorder scale

Effect of Pseudoephedrine on 800-m-Run Times of Female Collegiate Track Athletes

Contact Info

Product

Resources

About